Loading clinical trials...
Loading clinical trials...
A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)
Conditions
Interventions
BI 1467335
Placebo
Locations
35
United States
Trinity Research
Dothan, Alabama, United States
Retinal Research Institute, LLC
Phoenix, Arizona, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Florida Retina Institute
Orlando, Florida, United States
Northwestern Medical Group
Chicago, Illinois, United States
Start Date
September 19, 2017
Primary Completion Date
May 14, 2020
Completion Date
May 14, 2020
Last Updated
June 4, 2021
NCT07351786
NCT03713268
NCT03135327
NCT06782997
NCT06787482
NCT05147701
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions